Related Experiment Video
Updated: Jun 28, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in
Lisa Marie Fröhlich1, Ana Villar-Miyar1, Tamara Heintze1
1Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Abstract:
Metastatic melanoma is still a difficult-to-treat cancer type owing to its frequent resistance mechanisms to targeted and immunotherapy. Therefore, we aimed to unravel novel therapeutic strategies for melanoma patients. Preclinical and clinical studies show that melanoma patients may benefit from a treatment with poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). In this study, we focus on PARP1 as a potential biomarker to predict the response of melanoma cells to PARPi therapy. We found that melanoma cells with high basal PARP1 expression exhibit significantly increased cell death after PARPi treatment owing to higher PARP1 trapping compared with melanoma cells with low PARP1 expression. In addition, we could demonstrate that PARP1 expression levels are low in nonmalignant skin cells, and metastatic melanomas show considerably higher PARP1 levels compared with primary melanomas. Most strikingly, we found that high PARP1 levels correlate with worse overall survival of late stage metastasized melanoma patients. In conclusion, we show that PARP1 might act as a biomarker to predict the response to PARPi therapy, and that in particular the late stage metastasized melanoma patients are especially sensitive to PARPi therapy owing to elevated PARP1 expression. Our data suggest that the PARPi cytotoxicity primarily will affect the high PARP1 expressing melanoma cells, rather than the low PARP1 expressing nonmalignant skin cells resulting in only low side effects.
Insights
Poly (ADP-ribose) polymerase inhibitors (PARPi) show promise for treating melanoma. High PARP1 expression in melanoma cells predicts increased cell death with PARPi, suggesting PARP1 as a predictive biomarker for effective melanoma treatment.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Metastatic melanoma presents significant treatment challenges due to resistance to current therapies.
- Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are emerging as a potential therapeutic strategy for melanoma patients.
- Identifying biomarkers to predict treatment response is crucial for optimizing melanoma therapy.
Purpose of the Study:
- To investigate poly (ADP-ribose) polymerase 1 (PARP1) as a predictive biomarker for response to PARP inhibitors (PARPi) in melanoma.
- To evaluate the correlation between PARP1 expression levels and sensitivity to PARPi treatment in melanoma cells.
- To assess the differential expression of PARP1 in melanoma cells versus nonmalignant skin cells.
Main Methods:
- Analysis of PARP1 expression levels in melanoma cell lines and patient samples.
- Treatment of melanoma cells with varying PARP1 expression levels using PARP inhibitors (PARPi).
- Assessment of cell death and PARP1 trapping following PARPi treatment.
- Comparison of PARP1 expression in primary melanoma, metastatic melanoma, and nonmalignant skin cells.
Main Results:
- Melanoma cells with high basal PARP1 expression demonstrated significantly increased cell death upon PARPi treatment due to enhanced PARP1 trapping.
- PARP1 expression levels were found to be low in nonmalignant skin cells.
- Metastatic melanomas exhibited considerably higher PARP1 levels compared to primary melanomas.
- High PARP1 levels correlated with worse overall survival in late-stage metastasized melanoma patients.
Conclusions:
- PARP1 serves as a potential biomarker for predicting response to PARPi therapy in melanoma.
- Late-stage metastasized melanoma patients with elevated PARP1 expression are particularly sensitive to PARPi therapy.
- PARPi-induced cytotoxicity is likely to target high PARP1-expressing melanoma cells, minimizing effects on low PARP1-expressing nonmalignant skin cells and potentially reducing side effects.
Related Concept Videos
02:23Abnormal Proliferation
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...